Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Background: No regulations govern placebo composition. The composition of placebos can influence trial outcomes and merits reporting. Purpose: To assess how often investigators specify the composition of placebos in randomized, placebo-controlled trials. Data Sources: 4 English-language general and internal medicine journals with high impact factors. Study Selection: 3 reviewers screened titles and abstracts of the journals to identify randomized, placebo-controlled trials published from January 2008 to December 2009. Data Extraction: Reviewers independently abstracted data from the introduction and methods sections of identified articles, recording treatment type (pill, injection, or other) and whether placebo composition was stated. Discrepancies were resolved by consensus. Data Synthesis: Most studies did not disclose the composition of the study placebo. Disclosure was less common for pills than for injections and other treatments (8.2% vs. 26.7%; P = 0.002). Limitation: Journals with high impact factors may not be representative. Conclusion: Placebos were seldom described in randomized, controlled trials of pills or capsules. Because the nature of the placebo can influence trial outcomes, placebo formulation should be disclosed in reports of placebo-controlled trials. Primary Funding Source: University of California Foundation Fund 3929 - Medical Reasoning. © 2010 American College of Physicians.

Type

Journal article

Journal

Annals of Internal Medicine

Publication Date

19/10/2010

Volume

153

Pages

532 - 535